** Shares of gene-sequencing equipment maker Illumina ILMN.O fall 2.7% to $94.6
** Bernstein analysts say Roche's ROG.S new gene sequencing device designed to decode diseases such as cancer, immune disorders and neurodegenerative diseases outperforms ILMN's devices
** ROG unveiled the device on Thursday, featuring gene sequencing capabilities that provides detailed insights into genetics, genomics and cell biology
** ILMN shares had closed down 5.6% on Thursday, following the news
** Bernstein raises questions about the accuracy of the ROG device but said it could be a serious threat to ILMN in some applications
** ILMN has fallen 24.8% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.